Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of KITE-363 in relapsed or refractory B-cell lymphoma
NL-OMON53464Phase 1Recruiting
- Sponsor
- Kite Pharma
- Start
- Nov 2021
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of KITE-363 in mature B-cell lymphoma, non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL) and 4 more (2 arms), sponsored by Kite Pharma. Primary endpoints: Dose-limiting toxicities and Objective response rate. Started Nov 2021; status: recruiting.
02
Drugs
KITE-363
03
Conditions
mature B-cell lymphomanon-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on NL-OMON53464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53464.